The benefits of medical innovation took center stage last week at the North Carolina Biotechnology Center, as researchers, patient advocates and pharmaceutical industry representatives gathered to reflect on the industry’s importance.
Read MoreDurham-based Biomarck Pharmaceuticals has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer.
Read More
Clinical data company TARGET PharmaSolutions of Chapel Hill has added to its stable of major pharmaceutical company strategic alliances by adding Novartis to its study of liver disease.
Read MoreNorth Carolina’s life science sector registered another run of robust growth in 2017, ending the year with more than 700 companies employing over 63,000 people. Here’s a recap.
Read MoreDurham-based CivaTech Oncology Inc., a company designing innovative low dose rate internal radiation products that combat cancer, has raised $15,000 of a $2 million debt offering, according to a regulatory filing.
Read More
Olav Rueppell, Ph.D., says his research on saving honeybee hives at the University of North Carolina Greensboro clearly illustrates how relatively small but timely grant funding from the North Carolina Biotechnology Center had a big impact.
Read MorePotential therapies for several rare diseases and cancers will be manufactured in Durham, according to Cambridge, Mass.-based bluebird bio, which has purchased a 125,000-square foot manufacturing site.
Read MoreThe North Carolina Biotechnology Center has announced the inaugural class of Pfizer-NCBiotech Distinguished Postdoctoral Fellows in Gene Therapy.
Read More
Camras Vision Inc., a Triangle-based ophthalmic medical device company, has raised over $3 million in a private stock offering, reports Emily Brice for North Carolina Business News Wire.
Read More
